- Formulation development of Mithra’s vaginal ring product candidate is complete
- The completion of a such complex process shows Mithra’s deep know-how in long acting complex therapeutical entities .
- Production of clinical batches for the final bioequivalence study can start
- The final objective is to transfer the technology to the CDMO in Flemalle
Liège, Belgium 30 March 2016 – Mithra announces the completion of formulation development of its vaginal ring product candidate, Myring. This significant milestone was reached in line with objectives and schedule and paves the way to the next phase of development, the production of clinical batches for the bioequivalence study.